(Q84540289)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

1 reference

2

Shahrokh F Shariat

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Yair Lotan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Bernd J Schmitz-Dräger

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Marta Sanchez-Carbayo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Feliksas Jankevicius

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Marco Racioppi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sarah J P Minner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Brigitte Stöhr

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Pier Francesco Bassi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

H Barton Grossman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

441-448

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

Challenges of cancer biomarker profiling

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Nomograms for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Systematic review of statistical methods used in molecular marker studies in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Guidelines for development of diagnostic markers in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

REporting recommendations for tumor MARKer prognostic studies (REMARK).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Early results of bladder-cancer screening in a high-risk population of heavy smokers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Long-term outcome of home dipstick testing for hematuria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Clinical practice. Microscopic hematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Immunocytology in the assessment of patients with asymptomatic microhaematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Immunocytology in the assessment of patients with asymptomatic hematuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Urothelial bladder cancer: biomarkers for detection and screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Expectant treatment of small, recurrent, low-grade, noninvasive tumors of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Detection of bladder cancer using a point-of-care proteomic assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Long-term outcome of hematuria home screening for bladder cancer in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Screening and prostate-cancer mortality in a randomized European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Reliability of the routine cytological diagnosis in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

How important is urinary cytology in the diagnosis of urological malignancies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Patterns of hematuria referral to urologists: does a gender disparity exist?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Clinical trial designs for prospective validation of biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

Clinical trial designs for predictive biomarker validation: one size does not fit all.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2009.11.004

10.1016/J.UROLONC.2009.11.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20610281%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference